Chinook Therapeutics (KDNY) 10-Q 7 Aug 23 2023 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2023	Aug. 04, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Document Quarterly Report	true
Document Transition Report	false
Trading Symbol	KDNY
Security Exchange Name	NASDAQ
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Entity Interactive Data Current	Yes
Entity Registrant Name	CHINOOK THERAPEUTICS, INC.
Entity Central Index Key	0001435049
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		71,804,977
Entity Current Reporting Status	Yes
Entity File Number	001-37345
Entity Tax Identification Number	94-3348934
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	400 Fairview Avenue North, Suite 900
Entity Address, City or Town	Seattle
Entity Address, State or Province	WA
Entity Address Postal Zip Code	98109
City Area Code	(206)
Local Phone Number	485-7241

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 127,149	$ 115,438
Marketable securities	170,016	262,887
Accounts receivable	3,102	1,091
Prepaid expenses and other current assets	5,150	6,176
Total current assets	305,417	385,592
Marketable securities	1,972	6,989
Property and equipment, net	16,235	16,908
Restricted cash	2,074	2,074
Operating lease right-of-use assets	42,874	48,970
Investment in equity securities	41,200	41,200
Equity method investment	4,784	4,071
Intangible assets, net	23,421	24,287
In-process research & development	36,550	36,550
Goodwill	117	117
Other assets	14,167	7,326
Total assets	488,811	574,084
Current liabilities:
Accounts payable	16,362	9,751
Accrued and other current liabilities	29,342	33,636
Operating lease liabilities	4,268	4,948
Contingent value rights liability	2,500	2,500
Total current liabilities	52,472	50,835
Contingent value rights liability - non-current	40,217	37,318
Contingent consideration liability	4,290	4,420
Deferred tax liabilities	5,076	5,076
Operating lease liabilities, net of current maturities	29,717	34,494
Total liabilities	131,772	132,143
Commitments and contingencies (Note 12)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000 shares authorized as of June 30, 2023 and December 31, 2022; no shares issued and outstanding at June 30, 2023 and December 31, 2022
Common stock, $0.0001 par value; 300,000 shares authorized as of June 30, 2023 and December 31, 2022; 67,079 and 65,471 shares issued and outstanding at June 30, 2023 and December 31, 2022	7	7
Additional paid-in capital	905,109	864,729
Accumulated deficit	(546,752)	(419,631)
Accumulated other comprehensive loss	(1,325)	(3,164)
Total stockholders’ equity	357,039	441,941
Total liabilities and stockholders’ equity	$ 488,811	$ 574,084

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock par value per share	$ 0.0001	$ 0.0001
Preferred stock shares authorized	10,000,000	10,000,000
Preferred stock shares issued	0	0
Preferred stock shares outstanding	0	0
Common stock par value per share	$ 0.0001	$ 0.0001
Common stock shares authorized	300,000,000	300,000,000
Common stock shares issued	67,079,000	65,471,000
Common stock shares outstanding	67,079,000	65,471,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Statement of Comprehensive Income [Abstract]
Collaboration and license revenue	$ 1,008	$ 418	$ 2,836	$ 3,115
Operating expenses:
Research and development	57,897	30,023	108,780	56,275
General and administrative	13,061	8,635	24,465	16,503
Change in fair value of contingent consideration and contingent value rights liabilities	2,243	(1,984)	2,769	(3,022)
Amortization of intangible assets	433	429	866	858
Total operating expenses	73,634	37,103	136,880	70,614
Loss from operations	(72,626)	(36,685)	(134,044)	(67,499)
Investment and other income, net	3,670	767	6,772	672
Loss before income taxes and equity method investment gain (loss)	(68,956)	(35,918)	(127,272)	(66,827)
Equity method investment gain (loss)	2,012	(1,730)	151	(2,505)
Net loss	$ (66,944)	$ (37,648)	$ (127,121)	$ (69,332)
Net loss per share attributable to common stockholders, basic	$ (0.94)	$ (0.61)	$ (1.79)	$ (1.15)
Net loss per share attributable to common stockholders, diluted	$ (0.94)	$ (0.61)	$ (1.79)	$ (1.15)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	71,592	61,983	71,150	60,175
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	71,592	61,983	71,150	60,175
Other comprehensive income (loss):
Foreign currency translation adjustments, net of tax of $0	$ (25)	$ (501)	$ 445	$ (394)
Unrealized gain (loss) on marketable debt securities, net of tax of $0	411	(493)	1,394	(2,082)
Total other comprehensive income (loss)	386	(994)	1,839	(2,476)
Comprehensive loss	$ (66,558)	$ (38,642)	$ (125,282)	$ (71,808)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Statement of Comprehensive Income [Abstract]
Foreign currency translation adjustments, tax	$ 0	$ 0	$ 0	$ 0
Unrealized gain (loss) on marketable debt securities, tax	$ 0	$ 0	$ 0	$ 0

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)
Beginning balance at Dec. 31, 2021	$ 453,643	$ 5	$ 685,459	$ (231,766)	$ (55)
Beginning balance, Shares at Dec. 31, 2021		54,761
Issuance of common stock upon exercise of stock options and vesting of restricted stock units, shares		356
Issuance of common stock upon exercise of stock options and vesting of restricted stock units	2,049	$ 1	2,048
Stock-based compensation expense	4,269		4,269
Other comprehensive income (loss)	(1,482)				(1,482)
Net Income (Loss)	(31,684)			(31,684)
Ending balance at Mar. 31, 2022	426,795	$ 6	691,776	(263,450)	(1,537)
Ending balance, Shares at Mar. 31, 2022		55,117
Beginning balance at Dec. 31, 2021	453,643	$ 5	685,459	(231,766)	(55)
Beginning balance, Shares at Dec. 31, 2021		54,761
Net Income (Loss)	(69,332)
Ending balance at Jun. 30, 2022	507,131	$ 6	810,754	(301,098)	(2,531)
Ending balance, Shares at Jun. 30, 2022		62,873
Beginning balance at Mar. 31, 2022	426,795	$ 6	691,776	(263,450)	(1,537)
Beginning balance, Shares at Mar. 31, 2022		55,117
Issuance of common stock upon exercise of stock options issuance of common stock under employee stock purchase plan and vesting of restricted stock units, shares		202
Issuance of common stock upon exercise of stock options, issuance of common stock under Employee Stock Purchase Plan, and vesting of restricted stock units	1,136		1,136
Issuance of common stock and accompanying pre funded warrants in underwritten public offering, net of issuance costs, shares		7,554
Issuance of common stock and accompanying pre funded warrants in underwritten public offering, net of issuance costs	113,082		113,082
Stock-based compensation expense	4,760		4,760
Other comprehensive income (loss)	(994)				(994)
Net Income (Loss)	(37,648)			(37,648)
Ending balance at Jun. 30, 2022	507,131	$ 6	810,754	(301,098)	(2,531)
Ending balance, Shares at Jun. 30, 2022		62,873
Beginning balance at Dec. 31, 2022	$ 441,941	$ 7	864,729	(419,631)	(3,164)
Beginning balance, Shares at Dec. 31, 2022	65,471	65,471
Issuance of common stock upon exercise of stock options and vesting of restricted stock units, shares		432
Issuance of common stock upon exercise of stock options and vesting of restricted stock units	$ 1,666		1,666
Issuance Of Common Stock Under At Market Sales Agreement Net Of Offering Costs Shares		919
Issuance Of Common Stock Under At Market Sales Agreement Net Of Offering Costs	19,600		19,600
Stock-based compensation expense	7,910		7,910
Other comprehensive income (loss)	1,453				1,453
Net Income (Loss)	(60,177)			(60,177)
Ending balance at Mar. 31, 2023	412,393	$ 7	893,905	(479,808)	(1,711)
Ending balance, Shares at Mar. 31, 2023		66,822
Beginning balance at Dec. 31, 2022	$ 441,941	$ 7	864,729	(419,631)	(3,164)
Beginning balance, Shares at Dec. 31, 2022	65,471	65,471
Net Income (Loss)	$ (127,121)
Ending balance at Jun. 30, 2023	$ 357,039	$ 7	905,109	(546,752)	(1,325)
Ending balance, Shares at Jun. 30, 2023	67,079	67,079
Beginning balance at Mar. 31, 2023	$ 412,393	$ 7	893,905	(479,808)	(1,711)
Beginning balance, Shares at Mar. 31, 2023		66,822
Issuance of common stock upon exercise of stock options issuance of common stock under employee stock purchase plan and vesting of restricted stock units, shares		257
Issuance of common stock upon exercise of stock options, issuance of common stock under Employee Stock Purchase Plan, and vesting of restricted stock units	2,012		2,012
Stock-based compensation expense	9,192		9,192
Other comprehensive income (loss)	(386)				(386)
Net Income (Loss)	(66,944)			(66,944)
Ending balance at Jun. 30, 2023	$ 357,039	$ 7	$ 905,109	$ (546,752)	$ (1,325)
Ending balance, Shares at Jun. 30, 2023	67,079	67,079

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Cash Flows from Operating Activities
Net loss			$ (127,121)	$ (69,332)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense			2,351	1,702
Loss on disposal of property and equipment				234
Amortization of intangible assets	$ 433	$ 429	866	858
Non-cash operating lease expense			3,062	3,092
Stock-based compensation expense	9,192	4,760	17,102	9,029
Change in fair value of contingent consideration and contingent value rights liabilities	2,243	(1,984)	2,769	(3,022)
Accretion of discounts and amortization of premiums on marketable securities			(2,704)	706
Equity method investment (gain) loss	(2,012)	1,730	(151)	2,505
Gain on termination of lease			(253)
Changes in operating assets and liabilities:
Accounts receivable			(2,011)	6,946
Prepaid expenses and other assets			(5,807)	(2,503)
Accounts payable			6,523	(3,723)
Accrued and other liabilities			(4,314)	273
Operating lease liabilities			(2,175)	(2,105)
Net cash used in operating activities			(111,863)	(55,340)
Cash Flows from Investing Activities
Purchases of marketable securities			(91,614)	(152,213)
Proceeds from marketable securities			193,600	63,479
Purchases of property and equipment			(1,546)	(601)
Net cash provided by (used in) investing activities			100,440	(89,335)
Cash Flows from Financing Activities
Proceeds from exercise of stock options and warrants and from Employee Stock Purchase Plan			3,678	3,185
Proceeds from at-the-market-sales agreement, net of issuance costs			19,600
Proceeds from issuance of common stock and accompanying pre-funded warrants in underwritten public offering, net of issuance costs				113,505
Previously incurred issuance costs related to an underwritten public offering paid during period				(286)
Payment of contingent value rights liability				(7,500)
Net cash provided by financing activities			23,278	108,904
Effect of exchange rate changes on cash, cash equivalents and restricted cash			(144)	(26)
Net decrease in cash, cash equivalents and restricted cash			11,711	(35,797)
Cash, cash equivalents and restricted cash at beginning of period			117,512	183,798
Cash, cash equivalents and restricted cash at end of period	129,223	148,001	129,223	148,001
Reconciliation of Cash, Cash Equivalents and Restricted Cash
Cash and cash equivalents	127,149	145,927	127,149	145,927
Restricted cash	2,074	2,074	2,074	2,074
Total cash, cash equivalents and restricted cash	$ 129,223	$ 148,001	129,223	148,001
Supplemental Cash Flow Information
Cash paid for amounts included in the measurement of lease liabilities			2,053	3,686
Change in right-of-use assets obtained in exchange for operating lease liabilities			(3,077)
Supplemental Disclosure of Non-Cash Investing and Financing Activities
Purchases of property and equipment included in accounts payable and in accrued and other current liabilities			344	87
Issuance costs incurred but unpaid				$ 423
Receivable from option exercises			$ 31

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022
Pay vs Performance Disclosure
Net Income (Loss)	$ (66,944)	$ (60,177)	$ (37,648)	$ (31,684)	$ (127,121)	$ (69,332)

Insider Trading Arrangements

Insider Trading Arrangements	6 Months Ended
	Jun. 30, 2023 shares
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	On June 6, 2023 , Michelle Griffin , a director on the Company’s board of directors, terminated a pre-arranged written stock sale plan previously adopted on March 8, 2023 in accordance with Rule 10b5-1, or the Griffin Rule 10b5-1 Plan, under the Exchange Act for the sale of up to 40% of net vested common shares from an RSU vesting as May 26, 2023. The Griffin Rule 10b5-1 Plan was entered into during an open trading window in accordance with our insider trading policy and was intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. On June 5, 2023 , Eric Bjerkholt , our Chief Financial Officer , terminated a pre-arranged written stock sale plan previously adopted on January 4, 2023 in accordance with Rule 10b5-1, or the Bjerkholt Rule 10b5-1 Plan, under the Exchange Act for the sale of up to 10,000 shares of our common stock. The Bjerkholt Rule 10b5-1 Plan was entered into during an open trading window in accordance with our insider trading policy and was intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. On June 5, 2023 , Andrew King , our Chief Scientific Officer , terminated a pre-arranged written stock sale plan previously adopted on December 2, 2022 in accordance with Rule 10b5-1, or the King Rule 10b5-1 Plan, under the Exchange Act for the sale of up to 25,000 shares of our common stock. The King Rule 10b5-1 Plan was entered into during an open trading window in accordance with our insider trading policy and was intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.
Michelle Griffin
Trading Arrangements, by Individual
Name	Michelle Griffin
Title	director
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	March 8, 2023
Rule 10b5-1 Arrangement Terminated	true
Termination Date	June 6, 2023
Eric Bjerkholt
Trading Arrangements, by Individual
Name	Eric Bjerkholt
Title	Chief Financial Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	January 4, 2023
Rule 10b5-1 Arrangement Terminated	true
Termination Date	June 5, 2023
Aggregate Available	10,000
Andrew King
Trading Arrangements, by Individual
Name	Andrew King
Title	Chief Scientific Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	December 2, 2022
Rule 10b5-1 Arrangement Terminated	true
Termination Date	June 5, 2023
Aggregate Available	25,000

Description of Business

Description of Business	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	1. Description of Business Chinook Therapeutics, Inc. (the “Company”, “Chinook”, “we”, “our”, or “us”) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing precision medicines for kidney diseases. Our lead clinical program is atrasentan, a potent and selective endothelin A receptor antagonist. We are currently conducting the phase 3 ALIGN trial of atrasentan for IgA nephropathy (“IgAN”) and the phase 2 AFFINITY basket trial for proteinuric glomerular diseases. Our second product candidate, BION-1301, or zigakibart, is an anti-APRIL monoclonal antibody also in phase 3 development for patients with IgAN. Our third product candidate is CHK-336, an oral small molecule lactate dehydrogenase inhibitor for the treatment of primary and idiopathic hyperoxaluria that is currently in phase 1 development. In addition, we are building our precision medicine pipeline through research and discovery programs for other rare, severe chronic kidney diseases. We were incorporated in Delaware and are headquartered in Seattle, Washington. Agreement and Plan of Merger In June 2023, we entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Novartis AG, a company organized under the laws of Switzerland (“Novartis”), and Cherry Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Merger Sub”). Subject to the terms and conditions of the Merger Agreement, Merger Sub will be merged with and into Chinook (the “Merger”), with Chinook surviving the Merger as a wholly owned subsidiary of Novartis. The Merger Agreement provides that at the effective time of the Merger (the “Effective Time”), each outstanding share of Company common stock, par value $ 0.0001 per share, will automatically be converted into the right to receive (i) $ 40.00 in cash, without interest and less any applicable withholding taxes, and (ii) one contractual contingent value right (“New CVR”) pursuant to the CVR Agreement to be entered into at or prior to the Effective Time of the Merger by Novartis and Computershare Trust Company, N.A. as rights agent (the “New CVR Agreement”). Following the consummation of the Merger, the Company will cease to be a publicly traded company. The consummation of the Merger is subject to certain closing conditions, including (i) the adoption of the Merger Agreement by the holders of a majority of the outstanding shares of Company common stock, (ii) the expiration or termination of the applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with such waiting period having expired on July 31, 2023 and (iii) the absence of any legal restraints that have the effect of preventing the consummation of the Merger. Moreover, each party’s obligation to consummate the Merger is subject to certain other conditions, including the accuracy of the other party’s representations and warranties in the Merger Agreement (subject to certain materiality qualifiers), the other party’s compliance in all material respects with its obligations under the Merger Agreement, the absence of any pending proceeding by a governmental entity and, to the extent required, certain other regulatory approvals. On August 2, 2023, our stockholders voted in favor of the adoption of the Merger Agreement. We expect to consummate the Merger on or about August 11, 2023.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation and Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and follow the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted, and accordingly the unaudited condensed consolidated financial statements do not include all of the information and notes required by U.S. GAAP for complete financial statements. These financial statements have been prepared on the same basis as our annual financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for a fair presentation of financial information. The results of operations for the three and six months ended June 30, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023 or for any other interim period or for any other future year. The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2022 included in our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on February 27, 2023. The unaudited condensed consolidated financial statements include the accounts of Chinook Therapeutics, Inc. and our wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of expenses during the reporting periods. Such estimates include the valuation of intangible assets, acquired property and equipment, investments, contingent value rights (“CVR”) liability, contingent consideration liability, lease right-of-use assets, and lease obligations, as well as accruals for research and development activities, stock-based compensation expense, and income taxes. Actual results could differ from those estimates. Significant Accounting Policies There have been no significant changes to the accounting policies during the six months ended June 30, 2023, as compared to the significant accounting policies described in Note 2 of the “Notes to Consolidated Financial Statements” in our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022 .

Reverse Merger and Contingent V

Reverse Merger and Contingent Value Rights	6 Months Ended
	Jun. 30, 2023
Business Combinations [Abstract]
Reverse Merger and Contingent Value Rights	3. Reverse Merger and Contingent Value Rights Chinook Therapeutics U.S., Inc. (“Private Chinook”) completed a merger with Aduro Biotech, Inc. (“Aduro”) on October 5, 2020 (the “Aduro Merger”). Refer to Note 1 “Description of Business” in our Annual Report on Form 10-K for the year ended December 31, 2022 for more information. At the effective time of the Aduro Merger, we also entered into an agreement pursuant to which Aduro’s common stockholders of record as of the close of business on October 2, 2020 received one CVR for each outstanding share of Aduro common stock held by such stockholder on such date (the “CVR Agreement”). Each CVR represents the contractual right to receive payments from us upon the receipt of consideration resulting from certain events described in the CVR Agreement, including taxes and certain other expenses.

Cash, Cash Equivalents and Mark

Cash, Cash Equivalents and Marketable Securities	6 Months Ended
	Jun. 30, 2023
Cash and Cash Equivalents [Abstract]
Cash, Cash Equivalents and Marketable Securities	4. Cash, Cash Equivalents and Marketable Securities Cash, cash equivalents and marketable securities consisted of the following (in thousands): June 30, 2023 Amortized Unrealized Unrealized Estimated Cash and cash equivalents: Cash $ 3,828 $ — $ — $ 3,828 Money market funds 71,998 — — 71,998 Commercial paper 14,461 — ( 2 ) 14,459 U.S. government and agency securities 36,852 12 — 36,864 Total cash and cash equivalents $ 127,139 $ 12 $ ( 2 ) $ 127,149 Marketable securities: Commercial paper $ 35,524 $ — $ ( 39 ) $ 35,485 U.S. government and agency securities 120,345 3 ( 538 ) 119,810 Corporate debt securities 16,785 — ( 92 ) 16,693 Total marketable securities $ 172,654 $ 3 $ ( 669 ) $ 171,988 December 31, 2022 Amortized Unrealized Unrealized Estimated Cash and cash equivalents: Cash $ 15,724 $ — $ — $ 15,724 Money market funds 45,443 — — 45,443 Commercial paper 41,972 — ( 15 ) 41,957 U.S. government and agency securities 12,311 3 — 12,314 Total cash and cash equivalents $ 115,450 $ 3 $ ( 15 ) $ 115,438 Marketable securities: Commercial paper $ 69,630 $ 2 $ ( 58 ) $ 69,574 U.S. government and agency securities 148,160 6 ( 1,461 ) 146,705 Corporate debt securities 54,123 — ( 526 ) 53,597 Total marketable securities $ 271,913 $ 8 $ ( 2,045 ) $ 269,876 The amortized cost and estimated fair value of our available-for-sale marketable securities by contractual maturity are summarized below as of June 30, 2023 (in thousands): Amortized Unrealized Unrealized Estimated Value Mature in one year or less $ 170,659 $ 1 $ ( 644 ) $ 170,016 Mature after one year through two years 1,995 2 ( 25 ) 1,972 Total available-for-sale marketable securities $ 172,654 $ 3 $ ( 669 ) $ 171,988 For all securities with a fair value less than its amortized cost basis, we determined the decline in fair value below amortized cost basis to be noncredit related. We have no t recognized any impairment losses through June 30, 2023 .

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	5. Fair Value Measurements We determine the fair value of certain financial assets and liabilities using the fair value of hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows: Level 1: Unadjusted quoted prices in active, accessible markets for identical assets or liabilities. Level 2: Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly. Level 3: Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable activity. The determination of a financial instrument’s level within the fair value hierarchy is based on an assessment of the lowest level of any input that is significant to the fair value measurement. We consider observable data to be market data which is readily available, regularly distributed or updated, reliable and verifiable, not proprietary, and provided by independent sources that are actively involved in the relevant market. The following tables present information about our financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands): June 30, 2023 Level 1 Level 2 Level 3 Total Assets: Cash and cash equivalents: Cash and money market funds $ 75,826 $ — $ — $ 75,826 Commercial paper — 14,459 — 14,459 U.S. government and agency securities — 36,864 — 36,864 Total cash and cash equivalents 75,826 51,323 — 127,149 Marketable securities: Commercial paper — 35,485 — 35,485 U.S. government and agency securities — 119,810 — 119,810 Corporate debt securities — 16,693 — 16,693 Total marketable securities — 171,988 — 171,988 Total fair value of assets $ 75,826 $ 223,311 $ — $ 299,137 Liabilities: Contingent value rights liability $ — $ — $ 42,717 $ 42,717 Contingent consideration liability — — 4,290 4,290 Total fair value of liabilities $ — $ — $ 47,007 $ 47,007 December 31, 2022 Level 1 Level 2 Level 3 Total Assets: Cash and cash equivalents: Cash and money market funds $ 61,167 $ — $ — $ 61,167 Commercial paper — 41,957 — 41,957 U.S. government and agency securities 12,314 12,314 Total cash and cash equivalents 61,167 54,271 — 115,438 Marketable securities: Commercial paper — 69,574 — 69,574 U.S. government and agency securities — 146,705 — 146,705 Corporate debt securities — 53,597 — 53,597 Total marketable securities — 269,876 — 269,876 Total fair value of assets $ 61,167 $ 324,147 $ — $ 385,314 Liabilities: Contingent value rights liability $ — $ — $ 39,818 $ 39,818 Contingent consideration liability — — 4,420 4,420 Total fair value of liabilities $ — $ — $ 44,238 $ 44,238 Money market funds are included within Level 1 of the fair value hierarchy because they are valued using quoted market prices. Other cash equivalents and marketable securities, such as commercial paper, U.S. government and agency securities, and corporate debt securities are classified within Level 2 of the fair value hierarchy as the valuation is obtained from third-party pricing services, which utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, estimated interest rates based on the issuer credit rating and term, and other observable inputs. The following table presents a summary of the changes in the fair value of our Level 3 financial instruments (in thousands): Contingent Contingent Balance at December 31, 2022 $ 39,818 $ 4,420 Net change in fair value upon remeasurement 2,899 ( 130 ) Balance at June 30, 2023 $ 42,717 $ 4,290 The fair values of the CVR and contingent consideration liabilities are based on significant unobservable inputs, which represent Level 3 measurements within the fair value hierarchy. In determining the fair value of the CVR and the contingent consideration liabilities, we used the income approach, primarily discounted cash flow models. The discounted cash flow models require the use of significant judgment, estimates and assumptions, including estimated revenues and costs, the probability of technical and regulatory success, and discount rates. The fair value of the CVR liability increased during the six months ended June 30, 2023 by $ 2.9 million primarily due to remeasuring the value of our preferred shares in Sairopa at estimated fair value mainly as a result of Sairopa executing a license agreement for its SIRPa inhibitor ADU-1805 with Exelixis, Inc. in November 2022. The contingent consideration liability did not change significantly during the six months ended June 30, 2023 . In addition, we will hold the shares in Sairopa until there is a liquidation event, at which time, in accordance with the CVR Agreement, 50 % of any net proceeds will accrue to the benefit of the CVR holders, net of deductions permitted under the CVR Agreement, including taxes and certain other expenses. Refer to Note 10 “Equity Method Investment” for more information.

Property and Equipment, Net

Property and Equipment, Net	6 Months Ended
	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	6. Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): June 30, December 31, 2023 2022 Research and lab equipment $ 3,640 $ 3,212 Computer equipment and software 2,733 1,670 Furniture and fixtures 1,354 1,351 Leasehold improvements 17,750 16,957 Construction in progress 339 895 Total property and equipment 25,816 24,085 Total accumulated depreciation ( 9,581 ) ( 7,177 ) Property and equipment, net $ 16,235 $ 16,908 Depreciation and amortization expense for property and equipment was $ 1.5 million and $ 0.8 million for the three months ended June 30, 2023 and 2022, respectively, and was $ 2.4 million and $ 1.7 million for the six months ended June 30, 2023 and 2022, respectively. Approximately $ 2.9 million of our property and equipment as of June 30, 2023 is located in Canada.

Intangible Assets

Intangible Assets	6 Months Ended
	Jun. 30, 2023
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Intangible Assets	7. Intangible Assets Intangible assets The gross carrying amounts and net book value of intangible assets were as follows (in thousands): June 30, 2023 Gross Carrying Accumulated Net Book Intangible assets with finite lives: Acquired license agreement $ 26,685 $ 4,322 $ 22,363 In-place lease 1,433 375 1,058 Total intangible assets with finite lives 28,118 4,697 23,421 Acquired in-process research & development ( ‟ IPR&D ˮ ) assets 36,550 — 36,550 Total intangible and acquired IPR&D assets $ 64,668 $ 4,697 $ 59,971 December 31, 2022 Gross Carrying Accumulated Net Book Intangible assets with finite lives: Acquired license agreement $ 26,685 $ 3,538 $ 23,147 In-place lease 1,433 293 1,140 Total intangible assets with finite lives 28,118 3,831 24,287 Acquired IPR&D assets 36,550 — 36,550 Total intangible and acquired IPR&D assets $ 64,668 $ 3,831 $ 60,837 Intangible assets are carried at cost less accumulated amortization and impairment. Amortization is over periods of 9 to 17 years, with an original weighted average period of 16.7 years, and the amortization expense is recorded in operating expenses. We test our acquired IPR&D assets for impairment on an annual basis, or more frequently if an impairment indicator exists. Amortization expense was $ 0.4 million for both the three months ended June 30, 2023 and 2022 and was $ 0.9 million for both the six months ended June 30, 2023 and 2022 . Based on finite-lived intangible assets recorded as of June 30, 2023 , the estimated future amortization expense for the next five years is as follows (in thousands): Year Ending December 31, Estimated 2023 (remaining six months) $ 866 2024 1,733 2025 1,733 2026 1,733 2027 1,733 Thereafter 15,623

Accrued and Other Current Liabi

Accrued and Other Current Liabilities	6 Months Ended
	Jun. 30, 2023
Accrued Liabilities and Other Liabilities [Abstract]
Accrued and Other Current Liabilities	8. Accrued and Other Current Liabilities Accrued and other current liabilities consisted of the following (in thousands): June 30, December 31, 2023 2022 Research and development costs $ 19,689 $ 21,970 Compensation and benefits 8,581 11,085 Sublease rent and security deposit — 157 Business taxes and licensing fees 45 — Consulting and outside services 971 403 Other 56 21 Total accrued and other current liabilities $ 29,342 $ 33,636

Investment in Equity Securities

Investment in Equity Securities	6 Months Ended
	Jun. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Investment in Equity Securities	9. Investment in Equity Securities In November 2021, we entered into agreements related to the formation of SanReno, a corporation established to develop, manufacture and commercialize kidney disease therapies in mainland China, Hong Kong, Macau, Taiwan and Singapore (collectively, the “Territory”). In connection with the formation of SanReno and pursuant to a license agreement entered into between Chinook and SanReno in November 2021 (the “China License Agreement”), Chinook granted SanReno exclusive licenses under certain intellectual property to develop and commercialize atrasentan and zigakibart in the Territory for use in all human indications. In return, Chinook received 40.0 million Series A preferred shares in SanReno representing 50 % ownership of the outstanding voting securities and a warrant to purchase a total of 5.0 million common shares of SanReno at an exercise price of $ 0.01 per share upon the attainment of regulatory exclusivity for atrasentan in the Territory. Such warrant will only be exercisable if and provided that SanReno obtains, before the 10-year anniversary of the closing of the formation of SanReno, the regulatory exclusivity for atrasentan in China for at least three years commencing from the New Drug Application approval by the National Medical Product Administration of China. The warrant will have a five-year exercise period after it becomes exercisable upon satisfaction of the exercise conditions and was valued at $ 1.2 million on the grant date based on the probability of exercise of the warrant and the market for such instruments. An investor syndicate led by Frazier Healthcare Partners and Pivotal bioVenture Partners China, along with existing Chinook investors Versant Ventures and Samsara BioCapital, invested $ 40.0 million in exchange for the remaining 50 % of the outstanding voting securities of SanReno. Refer to Note 11 “Collaboration and License Agreements” for more information regarding the China License Agreement. In connection with the formation of SanReno in November 2021, Chinook also entered into a Shareholders Agreement (the “Shareholders Agreement”) providing for certain rights and obligations of SanReno and its shareholders. Pursuant to the Shareholders Agreement, Chinook has the right to designate an individual for election to the board of directors of SanReno and SanReno has agreed that certain specified events (including certain liquidation events) shall require the approval of shareholders of SanReno holding a supermajority of SanReno’s Series A preferred shares. The Shareholders Agreement terminates by mutual consent of the parties, and automatically terminates upon the dissolution of SanReno or immediately prior to the consummation of a qualified initial public offering. We account for the investment in SanReno in accordance with the provisions of ASC Topic 321, Investments – Equity Securities , and elect to use the measurement alternative therein. As such, the investment is valued at $ 41.2 million as of June 30, 2023 , which was the total of the aggregate cost value of the 40.0 million preferred shares in SanReno received by us on the date of the closing of the formation of SanReno and the grant date value of the warrant. The investment will be re-measured upon future observable price changes(s) in orderly transaction(s) or upon impairment, if any. We have no t recognized any impairment losses through June 30, 2023. Pursuant to the terms of the Series A preferred stock, we are entitled to non-cumulative dividends at 8 % of our initial investment, payable when and if declared by the board of directors of SanReno. Dividends from our investment in equity securities, if declared, are reflected in the consolidated statements of operations and comprehensive loss. There were no dividends declared through June 30, 2023 .

Equity Method Investment

Equity Method Investment	6 Months Ended
	Jun. 30, 2023
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investment	10. Equity Method Investment In April 2021, we entered into a definitive agreement with Sairopa B.V., a private company created by Van Herk Royalty B.V. and D.S. Chahal (the “Sairopa Investors”) to acquire certain non-renal assets of Chinook in exchange for preferred stock in Sairopa. We will hold such shares until such time as there is a liquidation event, as defined in the shareholders agreement, in Sairopa. In accordance with the CVR Agreement, 50 % of any net proceeds received from this transaction by way of a liquidation event of Sairopa by October 4, 2030, net of deductions permitted under the CVR Agreement, including taxes and certain other expenses, will accrue to the benefit of the CVR holders. As of June 30, 2023 , we own a 36 % interest in Sairopa. We determined that we have the ability to exercise significant influence over Sairopa but do not have a controlling interest. Therefore, the investment in Sairopa was accounted for using the equity method. Judgment regarding the level of influence over each equity method investment includes considering key factors such as ownership interest, representation on the board of directors, and participation in policy-making decisions. The Sairopa Investors provided an initial capitalization of 12.5 million Euros. We recorded the equity method investment at $ 10.0 million, which is the fair value of the equity received by us in exchange for the non-renal assets. Our equity method investment was recorded at cost at inception and is adjusted each period for our share of the investee’s income or loss, which is reported in our consolidated statements of operations and comprehensive loss on a one quarter lag . In November 2022, Sairopa executed a license agreement with Exelixis, Inc (“Exelixis”). Under the terms of the agreement, Exelixis made an upfront payment of $ 40.0 million to obtain an exclusive, worldwide license to develop and commercialize ADU-1805 and other anti-SIRPα antibodies, and for certain expenses to be incurred by Sairopa in conducting phase 1 clinical studies of ADU-1805. Additionally, during the first quarter of 2023, Sairopa earned a $ 35.0 million milestone under the terms of the agreement. Sairopa is eligible to receive additional near-term development milestone payments totaling up to $ 62.5 million. Following the completion of certain clinical studies, Exelixis may exercise an option to continue the license agreement for $ 225.0 million based upon its evaluation of a pre-specified clinical data package to be delivered by Sairopa. Following the exercise of the option, Sairopa would be eligible to receive up to $ 465.0 million in additional development, commercial, and net sales milestone payments, as well as tiered royalties on future net sales of products. Our equity method investment is also adjusted each period for gains or losses from changes in our ownership interest in Sairopa, if any. We assess our equity method investment for impairment whenever events or changes in circumstances indicate that the carrying value of the investment may not be recoverable. We have no t recognized any impairment losses through June 30, 2023 .

Collaboration and License Agree

Collaboration and License Agreements	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaboration and License Agreements	11. Collaboration and License Agreements SanReno Therapeutics In November 2021, we entered into the China License Agreement, pursuant to which we granted SanReno exclusive licenses under certain intellectual property to develop, manufacture and commercialize for atrasentan and zigakibart in the Territory. Refer to Note 9 “Investment in Equity Securities” for further details on the agreements executed with SanReno. We evaluated the China License Agreement under ASC Topic 606 and determined that the China License Agreement represents a contract with a customer. We identified the following performance obligations: (i) the licenses to develop, manufacture and commercialize atrasentan and zigakibart; (ii) our obligation to transfer know-how for the licensed product candidates (“Technology Transfers”); (iii) manufacturing and supply services; and (iv) opt-in global studies. Refer to Note 11 “Collaboration and License Agreements” in our Annual Report on Form 10-K for the year ended December 31, 2022. Pursuant to the China License Agreement, SanReno will reimburse the manufacturing and supply services at cost plus a mark-up and will reimburse the opt-in global studies at cost, which represent pass-through fees from third-party vendors, including clinical research organization. Revenue attributable to the manufacturing and supply services and opt-in global studies will be recognized as incurred. For the three months ended June 30, 2023 and 2022, we recognized revenue of $ 0.7 million and $ 0.4 million, respectively, under the China License Agreement for costs reimbursed related to opt-in global studies and manufacturing and supply services. For the six months ended June 30, 2023 and 2022, we recognized revenue of $ 2.5 million and $ 3.1 million, respectively, under the China License Agreement for costs reimbursed related to opt-in global studies and manufacturing and supply services. We are also eligible to receive a progress-dependent milestone payment of up to approximately $ 25.0 million with respect to zigakibart. Under the China License Agreement, SanReno is also obligated to pay Chinook royalty payments at a percentage in the low teens based on net sales of atrasentan in the Territory on the portion of annual net sales in excess of a pre-determined amount, which royalty will be payable until the expiration of all licensed patents covering the sale of atrasentan in the Territory. The China License Agreement expires on a licensed product-by-licensed product basis on the latest of: (i) the expiration of the royalty term for atrasentan, (ii) the expiration of the last valid claim of a licensed patent for zigakibart in the Territory. The parties may terminate the China License Agreement pursuant to terms specified in the agreement. Chinook and SanReno also have reciprocal rights of first negotiation in their respective territories for certain future kidney disease products developed or in-licensed by either company. Chinook retains full rights to atrasentan and zigakibart outside of the Territory. The potential progress-dependent cash milestone payment that we are eligible to receive is fully constrained based on the probability of achievement. Accordingly, any future milestone payment received under the agreement will be recorded upon or over a period following receipt. Further, we will apply the exception under ASC Topic 606 for variable consideration related to sales-or-usage based royalties received in exchange for licensed intellectual property associated with atrasentan, therefore the royalties are not included in the transaction price until the licensee sells product. No progress-dependent milestone payments and royalties were earned during the three and six months ended June 30, 2023 and 2022. AbbVie Ireland Unlimited Company In December 2019, we entered into a license agreement (the “License Agreement”) with AbbVie Ireland Unlimited Company (“AbbVie”), which granted us an exclusive license to develop and commercialize atrasentan, an endothelin receptor antagonist. Under the agreement, we assumed all global development and commercialization responsibilities for atrasentan. In consideration of the license and rights granted under the License Agreement, we made an upfront cash payment and issued 2.0 million shares of common stock for total consideration of $ 6.7 million to AbbVie. We concluded that this transaction should be accounted for as an asset purchase, and as such, recorded the associated expense within research and development expense in the statements of operations and comprehensive loss, as the product has not reached technological feasibility and does not have alternative future use. Under the License Agreement, we are obligated to make contingent development, regulatory and commercial milestone payments of up to a maximum of $ 135.0 million in the aggregate, as well as pay royalties on the worldwide net sales of licensed products ranging from upper-single-digit to high-teen percentages. We did no t recognize any milestone payments for the three and six months ended June 30, 2023 and 2022. As of June 30, 2023 and December 31, 2022 , we did no t have any payable or receivable balances associated with the License Agreement. Merck In connection with the Aduro Merger, we became party to an agreement with Merck. The agreement sets forth the parties’ respective obligations for development, commercialization, regulatory and manufacturing and supply activities for antibody product candidates. All performance obligations of Aduro were completed prior to the Aduro Merger. We are eligible to receive future contingent payments, including up to $ 287.0 million in potential development milestone payments, and up to $ 135.0 million in commercial and net sales milestones for a product candidate. In addition, we are eligible to receive royalties at percentages in the mid-single digits to low teens based on net sales of the product. Future milestone payments and royalties will be recognized as revenue when earned as we have no performance obligations under this agreement. Any such milestones and royalties earned prior to October 4, 2030 will be payable by us to the CVR holders, net of deductions permitted under the CVR Agreement, including taxes and certain other expenses. Eli Lilly and Company In connection with the Aduro Merger, we assumed an ongoing research collaboration and exclusive license agreement with Eli Lilly and Company (“Lilly”) for the research and development of novel immunotherapies for autoimmune and other inflammatory diseases. Our only remaining performance obligation under the agreement was to perform research services through 2021, for which we were reimbursed up to a specified amount. We are eligible to receive future contingent milestone payments of up to approximately $ 463.0 million per licensed product and tiered royalties on net sales at percentages in the single digits. We determined that the potential milestone payments are not considered probable of being achieved and, accordingly, such milestones will be recognized as revenue when earned. We did no t recognize revenue for the three and six months ended June 30, 2023 and 2022 under the Lilly agreement.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	12. Commitments and Contingencies Leases We have a total of three operating leases as of June 30, 2023 with remaining lease terms of approximately 3 to 7 years. In June 2021 , we entered into a sublease agreement for office space in Seattle, Washington (“Seattle Sublease”), which we use as our corporate headquarters. The Seattle Sublease commenced on July 1, 2021 with an original lease term of 58 m onths. In April 2023, the sublandlord declared bankruptcy which terminated the Seattle Sublease. As a result, our Seattle Sublease term changed to a month-to-month basis with the landlord. Therefore, we derecognized the operating lease liabilities and assets related to this lease, which resulted in a gain of $ 0.3 million recorded in other income in the consolidated statements of operations and comprehensive loss. We also wrote-off $ 0.6 million of leasehold improvements related to this office space. As of June 30, 2023 , we are subleasing approximately 112,000 square feet in one of our facilities. Sublease income was $ 3.5 million and $ 2.0 million for the three months ended June 30, 2023 and 2022 , respectively, and was $ 5.3 million and $ 4.0 million for the six months ended June 30, 2023 and 2022 , respectively, which was netted against rent expense and is recorded as a component of general and administrative expenses in the consolidated statement of operations and comprehensive loss. Total sublease income to be earned, in aggregate, will be approximately $ 53.0 million over the remaining term of the sublease agreement. We maintain a letter of credit as security for a facility lease that expires in 2029 . The letter of credit is collateralized by a certificate of deposit in the amount of $ 1.8 million, which is classified as long-term restricted cash in our condensed consolidated balance sheet as of June 30, 2023 . Additionally, we maintain a letter of credit as a security deposit for a facility lease that expires in 2026 . The letter of credit is collateralized by a certificate of deposit in the amount of $ 0.3 million, which is classified as long-term restricted cash in our condensed consolidated balance sheet as of June 30, 2023. The maturity of our operating lease liabilities as of June 30, 2023 is as follows (in thousands): Undiscounted Lease Payments Amounts 2023 (remaining six months) $ 3,260 2024 6,590 2025 6,711 2026 6,706 2027 6,484 Thereafter 12,421 Total undiscounted lease payments 42,172 Present value adjustment ( 8,187 ) Total net lease liability $ 33,985 Net lease liability - current $ 4,268 Net lease liability - non-current 29,717 Total net lease liability $ 33,985 Rent expense recognized for operating leases was $ 2.3 million for both the three months ended June 30, 2023 and 2022 , respectively, and was $ 4.7 million for both the six months ended June 30, 2023 and 2022 . Variable lease payments, including non-lease components such as common area maintenance fees, recognized as rent expense for operating leases were $ 0.6 million and $ 0.8 million for the three months ended June 30, 2023 and 2022 , respectively, and were $ 1.6 million for both the six months ended June 30, 2023 and 2022. The following summarizes additional information related to our operating leases: June 30, December 31, Weighted-average remaining lease terms (in years) Operating leases 6.3 6.5 Weighted-average discount rate Operating leases 7.2 % 7.4 % Indemnification Agreements In the ordinary course of business, we enter into agreements that may include indemnification provisions. Pursuant to such agreements, we may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments we could be required to make under these provisions is not determinable. We have never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. We have also entered into indemnification agreements with our directors and officers that require us, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. We currently maintain directors’ and officers’ liability insurance. Legal Proceedings From time to time, we may become involved in litigation relating to claims arising from the ordinary course of business. Management believes that there are no actions pending against us currently, the ultimate disposition of which would have a material adverse effect on our results of operations, financial condition or cash flows. Other Commitments We have various manufacturing, clinical, research and other contracts with vendors in the conduct of the normal course of our business. All contracts are terminable, with varying provisions regarding termination. If a contract with a specific vendor were to be terminated, we would only be obligated for the products or services that we had received at the time the termination became effective as well as non-cancelable and non-refundable obligations, including payment obligations for costs or expenses incurred by the vendor for products or services before the termination became effective. In the case of terminating a clinical trial agreement at a particular site, we would also be obligated to provide continued support for appropriate medical procedures at that site until completion or termination.

Common Stock

Common Stock	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Common Stock	13. Common Stock At-the-Market Sales Agreement In April 2021, we entered into an “at-the-market” sales agreement (the “2021 Sales Agreement”), with Cantor Fitzgerald & Co. and SVB Securities LLC, previously known as SVB Leerink LLC, through which we may offer and sell shares of our common stock having an aggregate offering of up to $ 75.0 million through our sales agents, Cantor Fitzgerald & Co. and SVB Securities LLC. In November 2022, we amended the 2021 Sales Agreement to provide for offerings of up to $ 150.0 million. We will pay the sales agents a commission of up to 3 % of the gross proceeds of sales made through the 2021 Sales Agreement. In the first quarter of 2023, we sold 0.9 million shares for $ 19.6 million in net proceeds under the 2021 Sales Agreement. As of June 30, 2023 , we have $ 115.6 million remaining under the 2021 Sales Agreement, which is subject to the continued effectiveness of our automatic shelf registration statement on Form S-3 ASR (Registration No. 333-265168), or upon an effective replacement shelf registration statement.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	14. Stock-Based Compensation Equity Incentive Plans In 2019, Private Chinook adopted the 2019 Equity Incentive Plan (the “2019 Plan”). In connection with the Aduro Merger, we assumed Aduro’s two equity incentive plans, the Amended and Restated 2015 Equity Incentive Plan (the “2015 Plan”) and the 2009 Stock Incentive Plan (the “2009 Plan,” and collectively the “Aduro Plans” and together with the 2019 Plan, the “Plans”). No additional grants may be made from the 2009 Plan; however, shares subject to awards granted under the 2009 Plan remain subject to the terms of the 2009 Plan. In 2022, our board of directors approved the 2022 Employment Inducement Incentive Award Plan (the “2022 Inducement Plan”). We reserved 1.5 million shares of our common stock for issuance pursuant to awards to be granted under the 2022 Inducement Plan. The terms of the 2022 Inducement Plan are substantially similar to the terms of the Plans with the exception that awards may only be made to an employee who has not previously been an employee or member of our board of directors if the award is in connection with commencement of employment. As of June 30, 2023 and December 31, 2022 , there were 2.2 million and 2.1 million shares available for future grant, respectively, under the Plans and the 2022 Inducement Plan. In connection with the Aduro Merger, we assumed Aduro’s 2015 employee stock purchase plan (“2015 ESPP”). As of June 30, 2023 and December 31, 2022 , there were 1.7 million and 1.1 million shares available for future issuance under the 2015 ESPP, respectively. As of June 30, 2023, there was $ 0.3 million of total unrecognized compensation expense related to ESPP that is expected to be recognized over a weighted-average period of 0.4 years. Stock option activity und er the Plans and the 2022 Inducement Plan is set forth below: Number of Weighted- Weighted Aggregate Balance—December 31, 2022 6,127 $ 12.49 8.2 $ 85,766 Granted 2,048 24.55 Exercised ( 264 ) 9.39 Canceled or forfeited ( 70 ) 19.40 Balance—June 30, 2023 7,841 $ 15.68 8.2 $ 179,517 Options exercisable—June 30, 2023 3,146 $ 11.22 7.3 $ 86,835 Options vested and expected to vest—June 30, 2023 7,841 $ 15.68 8.2 $ 179,517 The aggregate intrinsic values of options outstanding, exercisable, and vested and expected to vest were calculated as the difference between the exercise price of the options and the market price for shares of our common stock as of June 30, 2023 . Options for 0.3 million and 0.4 million shares of our common stock were exercised during the six months ended June 30, 2023 and 2022 , respectively, with an intrinsic value of $ 4.0 million and $ 2.7 million, respectively. As of June 30, 2023, there was $ 56.1 million of total unrecognized compensation expense related to stock options that is expected to be recognized over a weighted-average period of 2.7 years. Restricted stock unit (“RSU”) activity under the Plans and the 2022 Inducement Plan is set forth below: RSUs Outstanding Number of Weighted- Value Per Balance—December 31, 2022 1,364 $ 15.33 Granted 701 24.46 Vested ( 360 ) 14.35 Canceled or forfeited ( 34 ) 19.39 Balance—June 30, 2023 1,671 $ 19.30 The total fair value of RSUs that vested in the six months ended June 30, 2023 and 2022 was $ 9.1 million and $ 2.2 million, respectively. As of June 30, 2023, there was $ 25.9 million of total unrecognized compensation expense related to RSUs that is expected to be recognized over a weighted-average period of 1.8 years. Performance share unit (“PSU”) activity under the Plans is set forth below: PSUs Outstanding Number of Weighted- Balance—December 31, 2022 812 $ 22.00 Canceled or forfeited ( 28 ) 21.75 Balance—June 30, 2023 784 $ 22.00 In 2022, we granted PSUs to our employees under the Plans. The vesting of these awards is subject to the achievement of specified regulatory performance targets. As of June 30, 2023, there was $ 17.3 million of total unrecognized compensation expense related to these PSUs with performance targets that are considered not probable of achievement. Valuation Assumptions The weighted-average assumptions used to estimate the fair value of stock options under the Plans and the 2022 Inducement Plan using the Black-Scholes option-pricing model and the resulting weighted-average grant date fair value were as follows: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Assumptions: Expected term (in years) 6.3 6.2 6.3 6.2 Volatility 74.7 % 77.0 % 75.3 % 77.6 % Risk-free interest rate 3.5 % 2.9 % 3.6 % 2.0 % Dividend yield — — — — Six Months Ended June 30, 2023 2022 Fair Value: Weighted-average grant date fair value per share $ 16.98 $ 9.28 The weighted-average assumptions used to estimate the fair value of our common stock to be issued under the 2015 ESPP using a Black-Scholes option-pricing model and the resulting weighted-average grant date fair value were as follows: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Assumptions: Expected term (in years) 0.5 0.5 0.5 0.5 Volatility 50.1 % 57.1 % 50.1 % 57.1 % Risk-free interest rate 5.3 % 0.0 % 5.3 % 0.0 % Dividend yield — — — — Six Months Ended June 30, 2023 2022 Fair Value: Weighted-average grant date fair value per share $ 6.66 $ 4.29 Stock-Based Compensation Expense Total stock-based compensation expense recognized was as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Research and development $ 5,125 $ 2,355 $ 9,451 $ 4,540 General and administrative 4,067 2,405 7,651 4,489 Total stock-based compensation expense $ 9,192 $ 4,760 $ 17,102 $ 9,029

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	15. Income Taxes No income tax benefit or expense was recorded for the three and six months ended June 30, 2023 and 2022 . Our effective tax rate is lower than the statutory tax rate of 21 % primarily due to us maintaining a full valuation allowance against our net deferred tax assets.

Net Loss Per Common Share

Net Loss Per Common Share	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Net Loss Per Common Share	16. Net Loss per Common Share The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders, which excludes unvested restricted shares and shares which are legally outstanding, but subject to repurchase by us (in thousands, except per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Numerator: Net loss attributable to common stockholders $ ( 66,944 ) $ ( 37,648 ) $ ( 127,121 ) $ ( 69,332 ) Denominator: Weighted-average shares outstanding 71,592 62,040 71,151 60,244 Less: weighted-average unvested restricted — ( 57 ) ( 1 ) ( 69 ) Weighted-average shares used in computing net 71,592 61,983 71,150 60,175 Net loss per share attributable to common $ ( 0.94 ) $ ( 0.61 ) ( 1.79 ) ( 1.15 ) As of June 30, 2023 and 2022, 4.6 million and 3.6 million pre-funded warrants to purchase common stock, respectively, issued in connection with the November 2021 and May 2022 public offerings, were included in the weighted-average shares outstanding used in the calculation of basic and diluted net loss per share. In the third quarter of 2023, 4.6 million pre-funded warrants were exercised. The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the period presented because including them would have been antidilutive (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Unvested RSUs 1,671 1,286 1,671 1,286 Unvested RSAs — 46 — 46 Unvested PSUs 784 — 784 — Options to purchase common stock 7,841 6,987 7,841 6,987 Total 10,296 8,319 10,296 8,319

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation and Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and follow the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted, and accordingly the unaudited condensed consolidated financial statements do not include all of the information and notes required by U.S. GAAP for complete financial statements. These financial statements have been prepared on the same basis as our annual financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for a fair presentation of financial information. The results of operations for the three and six months ended June 30, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023 or for any other interim period or for any other future year. The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2022 included in our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on February 27, 2023. The unaudited condensed consolidated financial statements include the accounts of Chinook Therapeutics, Inc. and our wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of expenses during the reporting periods. Such estimates include the valuation of intangible assets, acquired property and equipment, investments, contingent value rights (“CVR”) liability, contingent consideration liability, lease right-of-use assets, and lease obligations, as well as accruals for research and development activities, stock-based compensation expense, and income taxes. Actual results could differ from those estimates.

Cash, Cash Equivalents and Ma_2

Cash, Cash Equivalents and Marketable Securities (Tables)	6 Months Ended
	Jun. 30, 2023
Cash and Cash Equivalents [Abstract]
Summary of Cash, Cash Equivalents and Marketable Securities	Cash, cash equivalents and marketable securities consisted of the following (in thousands): June 30, 2023 Amortized Unrealized Unrealized Estimated Cash and cash equivalents: Cash $ 3,828 $ — $ — $ 3,828 Money market funds 71,998 — — 71,998 Commercial paper 14,461 — ( 2 ) 14,459 U.S. government and agency securities 36,852 12 — 36,864 Total cash and cash equivalents $ 127,139 $ 12 $ ( 2 ) $ 127,149 Marketable securities: Commercial paper $ 35,524 $ — $ ( 39 ) $ 35,485 U.S. government and agency securities 120,345 3 ( 538 ) 119,810 Corporate debt securities 16,785 — ( 92 ) 16,693 Total marketable securities $ 172,654 $ 3 $ ( 669 ) $ 171,988 December 31, 2022 Amortized Unrealized Unrealized Estimated Cash and cash equivalents: Cash $ 15,724 $ — $ — $ 15,724 Money market funds 45,443 — — 45,443 Commercial paper 41,972 — ( 15 ) 41,957 U.S. government and agency securities 12,311 3 — 12,314 Total cash and cash equivalents $ 115,450 $ 3 $ ( 15 ) $ 115,438 Marketable securities: Commercial paper $ 69,630 $ 2 $ ( 58 ) $ 69,574 U.S. government and agency securities 148,160 6 ( 1,461 ) 146,705 Corporate debt securities 54,123 — ( 526 ) 53,597 Total marketable securities $ 271,913 $ 8 $ ( 2,045 ) $ 269,876
Summary of Amortized Cost and Estimated Fair Value of Available-for-Sale Marketable Securities by Contractual Maturity	The amortized cost and estimated fair value of our available-for-sale marketable securities by contractual maturity are summarized below as of June 30, 2023 (in thousands): Amortized Unrealized Unrealized Estimated Value Mature in one year or less $ 170,659 $ 1 $ ( 644 ) $ 170,016 Mature after one year through two years 1,995 2 ( 25 ) 1,972 Total available-for-sale marketable securities $ 172,654 $ 3 $ ( 669 ) $ 171,988

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following tables present information about our financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands): June 30, 2023 Level 1 Level 2 Level 3 Total Assets: Cash and cash equivalents: Cash and money market funds $ 75,826 $ — $ — $ 75,826 Commercial paper — 14,459 — 14,459 U.S. government and agency securities — 36,864 — 36,864 Total cash and cash equivalents 75,826 51,323 — 127,149 Marketable securities: Commercial paper — 35,485 — 35,485 U.S. government and agency securities — 119,810 — 119,810 Corporate debt securities — 16,693 — 16,693 Total marketable securities — 171,988 — 171,988 Total fair value of assets $ 75,826 $ 223,311 $ — $ 299,137 Liabilities: Contingent value rights liability $ — $ — $ 42,717 $ 42,717 Contingent consideration liability — — 4,290 4,290 Total fair value of liabilities $ — $ — $ 47,007 $ 47,007 December 31, 2022 Level 1 Level 2 Level 3 Total Assets: Cash and cash equivalents: Cash and money market funds $ 61,167 $ — $ — $ 61,167 Commercial paper — 41,957 — 41,957 U.S. government and agency securities 12,314 12,314 Total cash and cash equivalents 61,167 54,271 — 115,438 Marketable securities: Commercial paper — 69,574 — 69,574 U.S. government and agency securities — 146,705 — 146,705 Corporate debt securities — 53,597 — 53,597 Total marketable securities — 269,876 — 269,876 Total fair value of assets $ 61,167 $ 324,147 $ — $ 385,314 Liabilities: Contingent value rights liability $ — $ — $ 39,818 $ 39,818 Contingent consideration liability — — 4,420 4,420 Total fair value of liabilities $ — $ — $ 44,238 $ 44,238
Summary of Changes in Fair Value of Level 3 Financial Instruments	The following table presents a summary of the changes in the fair value of our Level 3 financial instruments (in thousands): Contingent Contingent Balance at December 31, 2022 $ 39,818 $ 4,420 Net change in fair value upon remeasurement 2,899 ( 130 ) Balance at June 30, 2023 $ 42,717 $ 4,290

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	6 Months Ended
	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Summary of Property and Equipment, Net	Property and equipment, net consisted of the following (in thousands): June 30, December 31, 2023 2022 Research and lab equipment $ 3,640 $ 3,212 Computer equipment and software 2,733 1,670 Furniture and fixtures 1,354 1,351 Leasehold improvements 17,750 16,957 Construction in progress 339 895 Total property and equipment 25,816 24,085 Total accumulated depreciation ( 9,581 ) ( 7,177 ) Property and equipment, net $ 16,235 $ 16,908

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2023
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Schedule of Intangible Assets	The gross carrying amounts and net book value of intangible assets were as follows (in thousands): June 30, 2023 Gross Carrying Accumulated Net Book Intangible assets with finite lives: Acquired license agreement $ 26,685 $ 4,322 $ 22,363 In-place lease 1,433 375 1,058 Total intangible assets with finite lives 28,118 4,697 23,421 Acquired in-process research & development ( ‟ IPR&D ˮ ) assets 36,550 — 36,550 Total intangible and acquired IPR&D assets $ 64,668 $ 4,697 $ 59,971 December 31, 2022 Gross Carrying Accumulated Net Book Intangible assets with finite lives: Acquired license agreement $ 26,685 $ 3,538 $ 23,147 In-place lease 1,433 293 1,140 Total intangible assets with finite lives 28,118 3,831 24,287 Acquired IPR&D assets 36,550 — 36,550 Total intangible and acquired IPR&D assets $ 64,668 $ 3,831 $ 60,837
Schedule of Finite-Lived Intangible Assets Estimated Future Amortization Expense	Based on finite-lived intangible assets recorded as of June 30, 2023 , the estimated future amortization expense for the next five years is as follows (in thousands): Year Ending December 31, Estimated 2023 (remaining six months) $ 866 2024 1,733 2025 1,733 2026 1,733 2027 1,733 Thereafter 15,623

Accrued and Other Current Lia_2

Accrued and Other Current Liabilities (Tables)	6 Months Ended
	Jun. 30, 2023
Accrued Liabilities and Other Liabilities [Abstract]
Schedule of Accrued and Other Current Liabilities	Accrued and other current liabilities consisted of the following (in thousands): June 30, December 31, 2023 2022 Research and development costs $ 19,689 $ 21,970 Compensation and benefits 8,581 11,085 Sublease rent and security deposit — 157 Business taxes and licensing fees 45 — Consulting and outside services 971 403 Other 56 21 Total accrued and other current liabilities $ 29,342 $ 33,636

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Schedule of Maturity of Operating Lease Liabilities	The maturity of our operating lease liabilities as of June 30, 2023 is as follows (in thousands): Undiscounted Lease Payments Amounts 2023 (remaining six months) $ 3,260 2024 6,590 2025 6,711 2026 6,706 2027 6,484 Thereafter 12,421 Total undiscounted lease payments 42,172 Present value adjustment ( 8,187 ) Total net lease liability $ 33,985 Net lease liability - current $ 4,268 Net lease liability - non-current 29,717 Total net lease liability $ 33,985
Schedule of Additional Information Related to Operating Leases	The following summarizes additional information related to our operating leases: June 30, December 31, Weighted-average remaining lease terms (in years) Operating leases 6.3 6.5 Weighted-average discount rate Operating leases 7.2 % 7.4 %

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2023
Summary of Stock Option Activity	Stock option activity und er the Plans and the 2022 Inducement Plan is set forth below: Number of Weighted- Weighted Aggregate Balance—December 31, 2022 6,127 $ 12.49 8.2 $ 85,766 Granted 2,048 24.55 Exercised ( 264 ) 9.39 Canceled or forfeited ( 70 ) 19.40 Balance—June 30, 2023 7,841 $ 15.68 8.2 $ 179,517 Options exercisable—June 30, 2023 3,146 $ 11.22 7.3 $ 86,835 Options vested and expected to vest—June 30, 2023 7,841 $ 15.68 8.2 $ 179,517
Summary of Restricted Stock Unit ("RSU") Activity	Restricted stock unit (“RSU”) activity under the Plans and the 2022 Inducement Plan is set forth below: RSUs Outstanding Number of Weighted- Value Per Balance—December 31, 2022 1,364 $ 15.33 Granted 701 24.46 Vested ( 360 ) 14.35 Canceled or forfeited ( 34 ) 19.39 Balance—June 30, 2023 1,671 $ 19.30
Summary of PSU Activity	Performance share unit (“PSU”) activity under the Plans is set forth below: PSUs Outstanding Number of Weighted- Balance—December 31, 2022 812 $ 22.00 Canceled or forfeited ( 28 ) 21.75 Balance—June 30, 2023 784 $ 22.00
Schedule of Weighted-average Assumptions Used to Estimate Fair Value of Stock Options Using Black Scholes Option-Pricing Model	The weighted-average assumptions used to estimate the fair value of stock options under the Plans and the 2022 Inducement Plan using the Black-Scholes option-pricing model and the resulting weighted-average grant date fair value were as follows: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Assumptions: Expected term (in years) 6.3 6.2 6.3 6.2 Volatility 74.7 % 77.0 % 75.3 % 77.6 % Risk-free interest rate 3.5 % 2.9 % 3.6 % 2.0 % Dividend yield — — — — Six Months Ended June 30, 2023 2022 Fair Value: Weighted-average grant date fair value per share $ 16.98 $ 9.28
Summary of Stock-Based Compensation	Total stock-based compensation expense recognized was as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Research and development $ 5,125 $ 2,355 $ 9,451 $ 4,540 General and administrative 4,067 2,405 7,651 4,489 Total stock-based compensation expense $ 9,192 $ 4,760 $ 17,102 $ 9,029
2015 ESPP
Schedule of Black Scholes Option-Pricing Model	The weighted-average assumptions used to estimate the fair value of our common stock to be issued under the 2015 ESPP using a Black-Scholes option-pricing model and the resulting weighted-average grant date fair value were as follows: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Assumptions: Expected term (in years) 0.5 0.5 0.5 0.5 Volatility 50.1 % 57.1 % 50.1 % 57.1 % Risk-free interest rate 5.3 % 0.0 % 5.3 % 0.0 % Dividend yield — — — — Six Months Ended June 30, 2023 2022 Fair Value: Weighted-average grant date fair value per share $ 6.66 $ 4.29

Net Loss per Common Share (Tabl

Net Loss per Common Share (Tables)	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Schedule of Computation of Basic and Diluted Net Loss Per Share	The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders, which excludes unvested restricted shares and shares which are legally outstanding, but subject to repurchase by us (in thousands, except per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Numerator: Net loss attributable to common stockholders $ ( 66,944 ) $ ( 37,648 ) $ ( 127,121 ) $ ( 69,332 ) Denominator: Weighted-average shares outstanding 71,592 62,040 71,151 60,244 Less: weighted-average unvested restricted — ( 57 ) ( 1 ) ( 69 ) Weighted-average shares used in computing net 71,592 61,983 71,150 60,175 Net loss per share attributable to common $ ( 0.94 ) $ ( 0.61 ) ( 1.79 ) ( 1.15 )
Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share	The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the period presented because including them would have been antidilutive (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Unvested RSUs 1,671 1,286 1,671 1,286 Unvested RSAs — 46 — 46 Unvested PSUs 784 — 784 — Options to purchase common stock 7,841 6,987 7,841 6,987 Total 10,296 8,319 10,296 8,319

Description of Business - Addit

Description of Business - Additional Information (Details) - USD ($)	1 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Common stock par value per share	$ 0.0001	$ 0.0001
Novartis AG
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Common stock par value per share	$ 0.0001
Conversion of stock amount Issuable	$ 40

Reverse Merger and Contingent_2

Reverse Merger and Contingent Value Rights - Additional Information (Details)	6 Months Ended
	Jun. 30, 2023
Business Combinations [Abstract]
Description of contingent value rights granted	one CVR for each outstanding share of Aduro common stock

Cash, Cash Equivalents and Ma_3

Cash, Cash Equivalents and Marketable Securities - Summary of Cash, Cash Equivalents and Marketable Securities (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Cash And Cash Equivalents [Line Items]
Cash and cash equivalents, Amortized Cost	$ 127,139	$ 115,450
Cash and cash equivalents, Unrealized Gains	12	3
Cash and cash equivalents, Unrealized Losses	(2)	(15)
Cash and cash equivalents, Estimated Fair Value	127,149	115,438
Marketable securities, Amortized Cost	172,654	271,913
Marketable securities, Unrealized Gains	3	8
Marketable securities, Unrealized Losses	(669)	(2,045)
Marketable securities, Estimated Fair Value	171,988	269,876
Cash
Cash And Cash Equivalents [Line Items]
Cash and cash equivalents, Amortized Cost	3,828	15,724
Cash and cash equivalents, Estimated Fair Value	3,828	15,724
Money Market Funds
Cash And Cash Equivalents [Line Items]
Cash and cash equivalents, Amortized Cost	71,998	45,443
Cash and cash equivalents, Estimated Fair Value	71,998	45,443
Commercial Paper
Cash And Cash Equivalents [Line Items]
Cash and cash equivalents, Amortized Cost	14,461	41,972
Cash and cash equivalents, Unrealized Losses	(2)	(15)
Cash and cash equivalents, Estimated Fair Value	14,459	41,957
Marketable securities, Amortized Cost	35,524	69,630
Marketable securities, Unrealized Gains		2
Marketable securities, Unrealized Losses	(39)	(58)
Marketable securities, Estimated Fair Value	35,485	69,574
U.S. Government and Agency Securities
Cash And Cash Equivalents [Line Items]
Cash and cash equivalents, Amortized Cost	36,852	12,311
Cash and cash equivalents, Unrealized Gains	12	3
Cash and cash equivalents, Estimated Fair Value	36,864	12,314
Marketable securities, Amortized Cost	120,345	148,160
Marketable securities, Unrealized Gains	3	6
Marketable securities, Unrealized Losses	(538)	(1,461)
Marketable securities, Estimated Fair Value	119,810	146,705
Corporate Debt Securities
Cash And Cash Equivalents [Line Items]
Marketable securities, Amortized Cost	16,785	54,123
Marketable securities, Unrealized Losses	(92)	(526)
Marketable securities, Estimated Fair Value	$ 16,693	$ 53,597

Cash, Cash Equivalents and Ma_4

Cash, Cash Equivalents and Marketable Securities - Summary of Amortized Cost and Estimated Fair Value of Available-for-Sale Marketable Securities by Contractual Maturity (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Mature in one year or less, Amortized Cost	$ 170,659
Mature after one year through two years, Amortized Cost	1,995
Marketable securities, Amortized Cost	172,654	$ 271,913
Mature in one year or less, Unrealized Gains	1
Mature after one year through two years, Unrealized Gains	2
Total available-for-sale marketable securities, Unrealized Gains	3	8
Mature in one year or less, Unrealized Losses	(644)
Mature after one year through two years, Unrealized Losses	(25)
Total available-for-sale marketable securities, Unrealized Losses	(669)	(2,045)
Mature in one year or less, Estimated Fair Value	170,016
Mature after one year through two years, Estimated Fair Value	1,972
Total available-for-sale marketable securities, Estimated Fair Value	$ 171,988	$ 269,876

Cash, Cash Equivalents and Ma_5

Cash, Cash Equivalents and Marketable Securities - Additional Information (Details)	6 Months Ended
	Jun. 30, 2023 USD ($)
Cash and Cash Equivalents [Abstract]
Impairement losses	$ 0

Fair Value Measurements - Finan

Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Assets:
Cash and cash equivalents, Estimated Fair Value	$ 127,149	$ 115,438
Marketable securities	171,988	269,876
Assets	299,137	385,314
Liabilities:
Liabilities	47,007	44,238
Contingent Value Rights Liability
Liabilities:
Liabilities	42,717	39,818
Contingent Consideration Liability
Liabilities:
Liabilities	4,290	4,420
Cash and Money Market Funds
Assets:
Cash and cash equivalents, Estimated Fair Value	75,826	61,167
Commercial Paper
Assets:
Cash and cash equivalents, Estimated Fair Value	35,485	41,957
Marketable securities	14,459	69,574
U.S. Government and Agency Securities
Assets:
Cash and cash equivalents, Estimated Fair Value	119,810	12,314
Marketable securities	36,864	146,705
Corporate Debt Securities
Assets:
Marketable securities	16,693	53,597
Level 1
Assets:
Cash and cash equivalents, Estimated Fair Value	75,826	61,167
Assets	75,826	61,167
Level 1 | Cash and Money Market Funds
Assets:
Cash and cash equivalents, Estimated Fair Value	75,826	61,167
Level 2
Assets:
Cash and cash equivalents, Estimated Fair Value	51,323	54,271
Marketable securities	171,988	269,876
Assets	223,311	324,147
Level 2 | Commercial Paper
Assets:
Cash and cash equivalents, Estimated Fair Value	35,485	41,957
Marketable securities	14,459	69,574
Level 2 | U.S. Government and Agency Securities
Assets:
Cash and cash equivalents, Estimated Fair Value	119,810	12,314
Marketable securities	36,864	146,705
Level 2 | Corporate Debt Securities
Assets:
Marketable securities	16,693	53,597
Level 3
Liabilities:
Liabilities	47,007	44,238
Level 3 | Contingent Value Rights Liability
Liabilities:
Liabilities	42,717	39,818
Level 3 | Contingent Consideration Liability
Liabilities:
Liabilities	$ 4,290	$ 4,420

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Financial Instruments (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)
Contingent Value Rights Liability
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Balance at December 31, 2022	$ 39,818
Net change in fair value upon remeasurement	2,899
Balance at June 30, 2023	42,717
Contingent Consideration Liability
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Balance at December 31, 2022	4,420
Net change in fair value upon remeasurement	(130)
Balance at June 30, 2023	$ 4,290

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - CVR Agreement $ in Millions	6 Months Ended
	Jun. 30, 2023 USD ($)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Increase (decrease) in fair value of contingent value rights liability	$ 2.9
Percentage of net proceeds received from transaction of liquidation event	50%

Property and Equipment, Net - S

Property and Equipment, Net - Summary of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Property Plant And Equipment [Line Items]
Total property and equipment	$ 25,816	$ 24,085
Total accumulated depreciation	(9,581)	(7,177)
Property and equipment, net	16,235	16,908
Research and Lab Equipment
Property Plant And Equipment [Line Items]
Total property and equipment	3,640	3,212
Computer Equipment and Software
Property Plant And Equipment [Line Items]
Total property and equipment	2,733	1,670
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Total property and equipment	1,354	1,351
Leasehold Improvements
Property Plant And Equipment [Line Items]
Total property and equipment	17,750	16,957
Construction in progress
Property Plant And Equipment [Line Items]
Total property and equipment	$ 339	$ 895

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Property Plant And Equipment [Line Items]
Property and equipment	$ 16,235		$ 16,235		$ 16,908
Depreciation and amortization expense for property and equipment	1,500	$ 800	2,400	$ 1,700
Canada
Property Plant And Equipment [Line Items]
Property and equipment	$ 2,900		$ 2,900

Intangible Assets - Schedule of

Intangible Assets - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Finite Lived Intangible Assets, Gross Carrying Amount	$ 28,118	$ 28,118
Finite Lived Intangible Assets, Accumulated Amortization	4,697	3,831
Intangible assets, net	23,421	24,287
Intangible Assets, Gross Carrying Amount	64,668	64,668
Intangible assets, Net Book Value	59,971	60,837
Acquired in-process research & development ("IPR&D") assets
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Indefinite-Lived Intangible Assets, Gross Carrying Amount	36,550	36,550
Indefinite-Lived Intangible Assets, Net Book Value	36,550	36,550
Acquired license agreement
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Finite Lived Intangible Assets, Gross Carrying Amount	26,685	26,685
Finite Lived Intangible Assets, Accumulated Amortization	4,322	3,538
Intangible assets, net	22,363	23,147
In Place Lease
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Finite Lived Intangible Assets, Gross Carrying Amount	1,433	1,433
Finite Lived Intangible Assets, Accumulated Amortization	375	293
Intangible assets, net	$ 1,058	$ 1,140

Intangible Assets - Additional

Intangible Assets - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Intangible Assets, Net (Excluding Goodwill) [Line Items]
Intangible assets, weighted average period			16 years 8 months 12 days
Amortization of intangible assets	$ 433	$ 429	$ 866	$ 858
Minimum
Intangible Assets, Net (Excluding Goodwill) [Line Items]
Intangible assets, amortization period	9 years		9 years
Maximum
Intangible Assets, Net (Excluding Goodwill) [Line Items]
Intangible assets, amortization period	17 years		17 years

Intangible Assets - Schedule _2

Intangible Assets - Schedule of Finite-Lived Intangible Assets Estimated Future Amortization Expense (Details) $ in Thousands	Jun. 30, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2023 (remaining six months)	$ 866
2024	1,733
2025	1,733
2026	1,733
2027	1,733
Thereafter	$ 15,623

Accrued and Other Current Lia_3

Accrued and Other Current Liabilities - Schedule of Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Accrued Liabilities and Other Liabilities [Abstract]
Research and development costs	$ 19,689	$ 21,970
Compensation and benefits	8,581	11,085
Sublease rent and security deposit	0	157
Business taxes and licensing fees	45
Consulting and outside services	971	403
Other	56	21
Total accrued and other current liabilities	$ 29,342	$ 33,636

Investment in Equity Securiti_2

Investment in Equity Securities - Additional Information (Details) - SanReno - USD ($) $ / shares in Units, shares in Millions	1 Months Ended	6 Months Ended
	Nov. 30, 2021	Jun. 30, 2023
Investment In Equity Securities [Line Items]
Investment in equity security, ownership percentage	50%
Investment in equity securities	$ 40,000,000
Impairment losses		$ 0
Warrants to purchase common shares	5
Exercise price of warrants	$ 0.01
Warrant exercise period	5 years
Fair value of warrant	$ 1,200,000
Equity securities invested amount	$ 40,000,000
Investment in equity security, remaining ownership percentage	50%
Investment in equity securities		41,200,000
Dividends declared on investment in equity securities		$ 0
Series A Preferred Stock
Investment In Equity Securities [Line Items]
Investment in equity securities	$ 40,000,000
Dividends percentage	8%

Equity Method Investment - Addi

Equity Method Investment - Additional Information (Details) € in Millions	1 Months Ended		6 Months Ended
	Nov. 30, 2022 USD ($)	Apr. 30, 2021 USD ($)	Jun. 30, 2023 USD ($)	Apr. 30, 2021 EUR (€)
Sairopa B.V.
Schedule Of Equity Method Investments [Line Items]
Equity method investment, ownership percentage			36%
Equity method investment, initial capitalization | €				€ 12.5
Equity method investment, recorded		$ 10,000,000
Equity method investment, income or loss recorded term			one quarter lag
Upfront payment	$ 40,000,000
Milestone earned under terms of agreement			$ 35,000,000
Potential near term milestone payments	62,500,000
Exercise an option upon evaluation of prespecified clinical data package	225,000,000
Potential development commercial and net sales milestone payments	$ 465,000,000
Impairments On Investment In Equity Securities			$ 0
CVR Agreement
Schedule Of Equity Method Investments [Line Items]
Percentage of net proceeds received from transaction of liquidation event			50%
CVR Agreement | Sairopa B.V.
Schedule Of Equity Method Investments [Line Items]
Percentage of net proceeds received from transaction of liquidation event		50%

Collaboration and License Agr_2

Collaboration and License Agreements - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
China License Agreement | SanReno
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized		$ 700,000	$ 400,000	$ 2,500,000	$ 3,100,000
Progress-dependent milestone payments and royalties received		0	0	0	0
China License Agreement | SanReno | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Progress-dependent milestone receivable				25,000,000
AbbVie Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Common stock shares issued	2,000,000
Proceeds from issuance of common stock	$ 6,700,000
Milestone payment		0	0	0	0
Payable related to license agreement		0		0		$ 0
Receivable related to license agreement		0		0		$ 0
AbbVie Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contingent development, regulatory and commercial milestone payments		135,000,000		135,000,000
Merck | Maximum | Product Candidate
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone amount eligible to receive for products or product candidates				287,000,000
Merck | Maximum | Product
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone amount eligible to receive for products or product candidates				135,000,000
Lilly Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized		$ 0	$ 0	0	$ 0
Lilly Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone amount eligible to receive for products or product candidates				$ 463,000,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) $ in Millions	1 Months Ended	3 Months Ended		6 Months Ended
	Jun. 30, 2021 USD ($)	Jun. 30, 2023 USD ($) ft² LeaseFacility	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($) ft² LeaseFacility	Jun. 30, 2022 USD ($)
Operating Leased Assets [Line Items]
Number of lease facility | LeaseFacility		3		3
Aggregate sublease income to be earned				$ 53
Lease expiration date				2029
Operating leases rent expense		$ 2.3	$ 2.3	$ 4.7	$ 4.7
Operating leases variable lease payments		0.6	0.8	1.6	1.6
Long-Term Restricted Cash
Operating Leased Assets [Line Items]
Security deposit		1.8		$ 1.8
Collateralized Certificate of Deposit
Operating Leased Assets [Line Items]
Lease expiration date				2026
Collateralized Certificate of Deposit | Long-Term Restricted Cash
Operating Leased Assets [Line Items]
Security deposit		0.3		$ 0.3
Seattle Sublease
Operating Leased Assets [Line Items]
Sublease agreement entered date	2021-06
Sublease commencement date	Jul. 01, 2021
Sublease period	58 months
Gain (loss) from derecognized operating lease liabilities and assets recorded in other income	$ 0.3
Write off lease improvements related to office space	$ 0.6
Sublease
Operating Leased Assets [Line Items]
Sublease Income		$ 3.5	$ 2	$ 5.3	$ 4
Sublease | C A
Operating Leased Assets [Line Items]
Total square footage of leased property | ft²		112,000		112,000
Minimum
Operating Leased Assets [Line Items]
Operating lease, remaining lease term		3 years		3 years
Maximum
Operating Leased Assets [Line Items]
Operating lease, remaining lease term		7 years		7 years

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Maturity of Company's Operating Lease Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
2023 (remaining six months)	$ 3,260
2024	6,590
2025	6,711
2026	6,706
2027	6,484
Thereafter	12,421
Total undiscounted lease payments	42,172
Present value adjustment	(8,187)
Total net lease liability	33,985
Net lease liability - current	4,268	$ 4,948
Net lease liability - non-current	29,717	$ 34,494
Total net lease liability	$ 33,985

Commitments and Contingencies_3

Commitments and Contingencies - Schedule of Additional Information Related to Operating Leases (Details)	Jun. 30, 2023	Dec. 31, 2022
Weighted-average remaining lease terms (in years)
Operating leases	6 years 3 months 18 days	6 years 6 months
Weighted-average discount rate
Operating leases	7.20%	7.40%

Common Stock - Additional Infor

Common Stock - Additional Information (Details) - At-the-Market Offering - 2021 Sales Agreement - Cantor Fitzgerald & Co. and SVB Securities LLC - USD ($) shares in Millions, $ in Millions	1 Months Ended		3 Months Ended	6 Months Ended
	Nov. 30, 2022	Apr. 30, 2021	Mar. 31, 2023	Jun. 30, 2023
Class Of Stock [Line Items]
Commission on sales of common stock, percentage		3%
Aggregate offering available for issuance of common stock				$ 115.6
Issuance of common stock (in shares)			0.9
Proceeds from issuance of common stock			$ 19.6
Maximum
Class Of Stock [Line Items]
Aggregate offering available for issuance of common stock		$ 75
Aggregate offering available for issuance of common stock	$ 150

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) $ in Millions	6 Months Ended
	Jun. 30, 2023 USD ($) IncentivePlan shares	Jun. 30, 2022 USD ($) shares	Dec. 31, 2022 shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock compensation expense	$ 56.1
Number of equity incentive plans | IncentivePlan	2
Number of shares available for future grant | shares	2,200,000		2,100,000
Weighted-average remaining vesting period (years)	2 years 8 months 12 days
Common Stock options exercised | shares	264,000	400,000
Intrinsic value of options exercised	$ 4	$ 2.7
Restricted Stock Units ("RSU")
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock compensation expense	$ 25.9
Weighted-average remaining vesting period (years)	1 year 9 months 18 days
Total fair value of restricted stock units vested during the period	$ 9.1	$ 2.2
Performance Based Share Units (PSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock compensation expense	$ 17.3
2009 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of common shares, may be granted | shares	0
2022 Inducement Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares of common stock for issuance pursuant to awards granted | shares	1,500,000
2015 ESPP
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for future grant | shares	1,700,000		1,100,000
Unrecognized stock compensation expense	$ 0.3
Weighted-average remaining vesting period (years)	4 months 24 days

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Number of Shares Underlying Options, Beginning balance	6,127
Number of Shares Underlying Options, Granted	2,048
Number of Shares Underlying Options, Exercised	(264)	(400)
Number of Shares Underlying Options, Cancelled or forfeited	(70)
Number of Shares Underlying Options, Ending balance	7,841		6,127
Number of Shares Underlying Options, Options exercisable	3,146
Number of Shares Underlying Options, Vested and expected to vest	7,841
Options Outstanding, Weighted-Average Exercise Price, Beginning balance	$ 12.49
Options Outstanding, Weighted-Average Exercise Price, Granted	24.55
Options Outstanding, Weighted-Average Exercise Price, Exercised	9.39
Options Outstanding, Weighted-Average Exercise Price, Canceled or forfeited	19.4
Options Outstanding, Weighted-Average Exercise Price, Ending balance	15.68		$ 12.49
Options Outstanding, Weighted-Average Exercise Price, Options exercisable	11.22
Options Outstanding, Weighted-Average Exercise Price, Options vested and expected to vest	$ 15.68
Options Outstanding, Weighted Average Remaining Contractual Term, Beginning balance	8 years 2 months 12 days		8 years 2 months 12 days
Options exercisable, Weighted Average Remaining Contractual Term	7 years 3 months 18 days
Options vested and expected to vest, Weighted Average Remaining Contractual Term	8 years 2 months 12 days
Options Outstanding, Aggregate Intrinsic Value, Balance	$ 85,766
Options Outstanding, Aggregate Intrinsic Value, Ending	179,517		$ 85,766
Options Outstanding, Aggregate Intrinsic Value, Options exercisable-June 30, 2023	86,835
Options Outstanding, Aggregate Intrinsic Value, Options vested and expected to vest-June 30, 2023	$ 179,517

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Restricted Stock Units ("RSU") Activity (Details) - Restricted Stock Units ("RSU") shares in Thousands	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Restricted Stock, Beginning balance | shares	1,364
Number of Restricted Stock, Granted | shares	701
Number of Restricted Stock, Vested | shares	(360)
Number of Restricted Stock, Forfeited | shares	(34)
Number of Restricted Stock, Ending balance | shares	1,671
Weighted-Average Grant Date Fair Value per Share, Beginning Balance | $ / shares	$ 15.33
Weighted-Average Grant Date Fair Value Per Share, Granted | $ / shares	24.46
Weighted-Average Grant Date Fair Value per Share, Vested | $ / shares	14.35
Weighted-Average Grant Date Fair Value Per Share, Forfeited | $ / shares	19.39
Weighted-Average Grant Date Fair Value per Share, Ending Balance | $ / shares	$ 19.30

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock-Based Compensation - Summary of PSU Activity (Details) - Performance Based Share Units (PSUs)	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Restricted Stock, Beginning balance | shares	812,000
Number of Restricted Stock, Canceled or forfeited | shares	(28,000)
Number of Restricted Stock, Ending balance | shares	784,000
Weighted-Average Grant Date Fair Value per Share, Beginning Balance | $ / shares	$ 22
Weighted-Average Grant Date Fair Value per Share, Canceled or forfeited | $ / shares	21.75
Weighted-Average Grant Date Fair Value per Share, Ending Balance | $ / shares	$ 22

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Weighted-average Assumptions Used to Estimate Fair Value of Stock Options Using Black Scholes Option-Pricing Model (Details) - Employee Stock Option - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	6 years 3 months 18 days	6 years 2 months 12 days	6 years 3 months 18 days	6 years 2 months 12 days
Volatility	74.70%	77%	75.30%	77.60%
Risk-free interest rate	3.50%	2.90%	3.60%	2%
Weighted-average grant date fair value per share			$ 16.98	$ 9.28

Stock-Based Compensation - Sc_2

Stock-Based Compensation - Schedule of Black Scholes Option-Pricing Model (Details) - 2015 ESPP - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	6 months	6 months	6 months	6 months
Volatility	50.10%	57.10%	50.10%	57.10%
Risk-free interest rate	5.30%	0%	5.30%	0%
Weighted-average grant date fair value per share			$ 6.66	$ 4.29

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of Stock-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 9,192	$ 4,760	$ 17,102	$ 9,029
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	5,125	2,355	9,451	4,540
General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 4,067	$ 2,405	$ 7,651	$ 4,489

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income tax expense (benefit)	$ 0	$ 0	$ 0	$ 0
Statutory tax rate			21%

Net Loss per Common Share - Sch

Net Loss per Common Share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022
Earnings Per Share [Abstract]
Net loss attributable to common stockholders	$ (66,944)	$ (60,177)	$ (37,648)	$ (31,684)	$ (127,121)	$ (69,332)
Weighted-average shares outstanding	71,592		62,040		71,151	60,244
Less: weighted-average unvested restricted shares and shares subject to repurchase			(57)		(1)	(69)
Weighted Average Number of Shares Outstanding, Basic, Total	71,592		61,983		71,150	60,175
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	71,592		61,983		71,150	60,175
Net loss per share attributable to common stockholders, basic	$ (0.94)		$ (0.61)		$ (1.79)	$ (1.15)
Net loss per share attributable to common stockholders, diluted	$ (0.94)		$ (0.61)		$ (1.79)	$ (1.15)

Net Loss Per Common Share - Add

Net Loss Per Common Share - Additional Information (Details) - Pre-Funded Warrants - shares shares in Millions	1 Months Ended
	Aug. 03, 2023	Jun. 30, 2023	Jun. 30, 2022
Earnings Per Share Basic [Line Items]
Pre-funded warrants to purchase common stock (in shares)		4.6	3.6
Subsequent Event
Earnings Per Share Basic [Line Items]
Number of warrants exercised	4.6

Net Loss per Common Share - S_2

Net Loss per Common Share - Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potential dilutive securities excluded from diluted net loss per share would have been antidilutive	10,296	8,319	10,296	8,319
Unvested RSUs
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potential dilutive securities excluded from diluted net loss per share would have been antidilutive	1,671	1,286	1,671	1,286
Unvested RSAs
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potential dilutive securities excluded from diluted net loss per share would have been antidilutive		46		46
Unvested PSUs
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potential dilutive securities excluded from diluted net loss per share would have been antidilutive	784		784
Options to Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potential dilutive securities excluded from diluted net loss per share would have been antidilutive	7,841	6,987	7,841	6,987